Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.
about
Standardization of sample collection, isolation and analysis methods in extracellular vesicle research.Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.Waldenström's macroglobulinaemia complicated by pure red cell aplasia: a case report.Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?Therapeutic effects of thalidomide in hematologic disorders: a review.Genetic factors and pathogenesis of Waldenström's macroglobulinemia.Renal involvement in Waldenström's macroglobulinemia: case report and review of literature.Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse modelsWaldenström macroglobulinemia: from biology to treatment.PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53.Determination of whole blood and plasma viscosity in term neonates by flow curve analysis with the LS300 viscometer1.Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.Positive selection and high sensitivity test for MYD88 mutations using locked nucleic acid.Severe immune thrombocytopenia secondary to Waldenström's macroglobulinemia with anti-GPIb/IX monoclonal IgM antibody.Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations.Long-term outcome of monoclonal (type 1) cryoglobulinemia.MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
P2860
Q34369038-5F17A9FB-9398-44CB-9D2F-6EF9F1D5ABD7Q35720912-9299CDA4-C1F9-4321-81F4-EC4058EBECA7Q37306808-DDF1F487-53F6-43FB-BB59-C2BDB4E79D22Q38045706-8339E1B5-3DF0-4137-8761-ADC6DB9A54C3Q38121762-6B371323-0545-4B77-96B2-C68DB7AE3122Q38125430-8B256ED6-60AC-49F9-A92D-F142B62318E5Q38141105-D73A6E26-6099-4811-8B7F-93C4D98122B2Q38150849-8DEF0326-1BD2-47EC-B6B0-3791FD5D83C3Q38176969-1E90C703-1436-419E-9DAA-550FB7902F59Q38895818-A56E11B0-8984-42C0-9862-EF0CCB8B3F11Q40458024-59F13A69-F452-4559-9A4D-7C0F774C729AQ46351985-3A14E98D-5804-4167-97BD-5BCE780A3BBFQ47887287-5A88298B-38F1-4513-9228-67A87BC2A07BQ47918270-B695DA66-383C-4593-942D-4A0490D743C2Q50696973-F1DE2108-5EEE-4581-A78F-F9DF59CD81BCQ50721391-ED8EFA10-B5A3-49A6-9ECB-920253D52A4AQ53089985-D5C523B0-CF60-464F-AA24-9BC5F7CC2751
P2860
Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Waldenström macroglobulinemia: ...... tratification, and management.
@ast
Waldenström macroglobulinemia: ...... tratification, and management.
@en
type
label
Waldenström macroglobulinemia: ...... tratification, and management.
@ast
Waldenström macroglobulinemia: ...... tratification, and management.
@en
prefLabel
Waldenström macroglobulinemia: ...... tratification, and management.
@ast
Waldenström macroglobulinemia: ...... tratification, and management.
@en
P2860
P356
P1476
Waldenström macroglobulinemia: ...... tratification, and management.
@en
P2860
P304
P356
10.1002/AJH.23192
P577
2012-05-01T00:00:00Z